1DNB student, National Institute of TB & Respiratory Diseases, Sri Aurobindo Marg, New Delhi, India
2HOD Epidemiology and Public Health, National Institute of TB & Respiratory Diseases, Sri Aurobindo Marg, New Delhi, India
3Senior Chest Physician, National Institute of TB & Respiratory Diseases, Sri Aurobindo Marg, New Delhi, India
4Director, National Institute of TB & Respiratory Diseases, Sri Aurobindo Marg, New Delhi, India
*Corresponding Author: Dr Sushil Michael Kundu, E-Mail ID: drsushil@gmail.com
Online published on 30 December, 2015.
To study the treatment outcome among New Smear Positive (NSP) patients, received direct observe treatment (DOT) during intensive phase.
Cross Sectional Study.
This study has been carried out among adult new smear positive Patients at DOT center of National Institute of TB & Respiratory Diseases, Sri Aurobindo Marg, New Delhi India. The study had been conducted on 50 patients receiving DOTS regimen from the period of August 2009 to January 2011. Sputum status at the end of Intensive phase and continuation phase was recorded by the treatment cards.
Out of the total 50 NSP Patients, 49 (98%) patients was receiving DOTS on their scheduled time and only 01(2%) patient had defaulted and missed doses on his schedule day, whereas no patient was on non DOTS. At the end of intensive phase 10 (20%) patient was extended while no extension was in 40 (80%) patients. 49 (98%) patients cured at the end of treatment while only 01 (2%) patient failure as per the RNTCP Guidelines.
Higher sputum Conversion and cure were achieved due to strict supervision and monitoring along with motivation of patients in treatment adherence.
Direct observe treatment, Intensive phase, Continuous phase, Conversion rate, Cure rate
